CTIC
CTI BioPharma Corp. [CTIC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CTIC Stock Summary
In the News
CTIC Financial details
Company Rating
Sell
Market Cap
1.2B
Income
-77.01M
Revenue
75.77M
Book val./share
-0.19
Cash/share
0.45
Dividend
-
Dividend %
-
Employees
127
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-15.54
Forward P/E
-
PEG
3.67
P/S
15.83
P/B
-47.21
P/C
-
P/FCF
-14.57
Quick Ratio
1.2
Current Ratio
1.27
Debt / Equity
-1.93
LT Debt / Equity
-
-
-
EPS (TTM)
-0.64
EPS next Y
-
EPS next Q
-
EPS this Y
-28.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.72%
Revenue last 5Y
15.46%
Revenue Q/Q
14.39%
EPS Q/Q
30.77%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
85.36%
Inst Trans
1.05%
ROA
-69%
ROE
474%
ROC
-1.22%
Gross Margin
94%
Oper. Margin
-71%
Profit Margin
-102%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.01-9.1
52W High
-
52W Low
-
RSI
-
Rel Volume
0.98
Avg Volume
5.66M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.830633
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
CTIC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.47 | 0.06 | 0 | 0 | 0.47 | |
| Net income per share | -0.52 | -0.73 | -0.74 | -1.11 | -0.79 | |
| Operating cash flow per share | -0.71 | -0.48 | -0.59 | -0.94 | -0.71 | |
| Free cash flow per share | -0.71 | -0.48 | -0.59 | -0.94 | -0.93 | |
| Cash per share | 1.2 | 0.58 | 0.74 | 0.73 | 0.7 | |
| Book value per share | 1.05 | 0.31 | 0.56 | 0.04 | -0.15 | |
| Tangible book value per share | 0.94 | 0.31 | 0.56 | 0.04 | -0.36 | |
| Share holders equity per share | 1.05 | 0.31 | 0.56 | 0.04 | -0.15 | |
| Interest debt per share | 0.28 | 0.24 | 0.09 | 0.59 | 0.55 | |
| Market cap | 41.14M | 91.6M | 229.07M | 223.49M | 689.31M | |
| Enterprise value | 18.78M | 72.71M | 193.94M | 208.6M | 708.85M | |
| P/E ratio | -1.4 | -2.16 | -4.33 | -2.24 | -7.57 | |
| Price to sales ratio | 1.56 | 27.38 | 0 | 0 | 12.78 | |
| POCF ratio | -1.03 | -3.29 | -5.43 | -2.63 | -8.49 | |
| PFCF ratio | -1.03 | -3.29 | -5.43 | -2.63 | -6.49 | |
| P/B Ratio | 0.7 | 5.11 | 5.72 | 59.33 | -39.22 | |
| PTB ratio | 0.7 | 5.11 | 5.72 | 59.33 | -39.22 | |
| EV to sales | 0.71 | 21.74 | 0 | 0 | 13.14 | |
| Enterprise value over EBITDA | -0.7 | -1.94 | -4.08 | -2.18 | -8.88 | |
| EV to operating cash flow | -0.47 | -2.61 | -4.6 | -2.46 | -8.73 | |
| EV to free cash flow | -0.47 | -2.61 | -4.59 | -2.46 | -6.68 | |
| Earnings yield | -0.71 | -0.46 | -0.23 | -0.45 | -0.13 | |
| Free cash flow yield | -0.97 | -0.3 | -0.18 | -0.38 | -0.15 | |
| Debt to equity | 0.24 | 0.68 | 0.13 | 13.42 | -2.84 | |
| Debt to assets | 0.16 | 0.26 | 0.09 | 0.7 | 0.4 | |
| Net debt to EBITDA | 0.83 | 0.5 | 0.74 | 0.16 | -0.24 | |
| Current ratio | 3.58 | 1.92 | 3.19 | 1.03 | 1.23 | |
| Interest coverage | -18.97 | -26.73 | -46.29 | -39.47 | -6.07 | |
| Income quality | 1.36 | 0.7 | 0.8 | 0.87 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.39 | 7.21 | 0 | 0 | 0.68 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0.18 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.31 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.46 | |
| Capex to depreciation | -0.06 | 0 | -0.03 | 0 | -12.81 | |
| Stock based compensation to revenue | 0.24 | 1.54 | 0 | 0 | 0.19 | |
| Graham number | 3.51 | 2.25 | 3.07 | 1.02 | 1.65 | |
| ROIC | -0.53 | -1.3 | -1.05 | -1.69 | -2.27 | |
| Return on tangible assets | -0.33 | -0.91 | -0.91 | -1.38 | -0.89 | |
| Graham Net | 0.72 | 0.09 | 0.48 | -0.04 | -0.45 | |
| Working capital | 59.44M | 17.09M | 37.29M | 1.73M | 18.26M | |
| Tangible asset value | 52.94M | 17.93M | 40.03M | 3.77M | -40.8M | |
| Net current asset value | 45.6M | 7.23M | 36.11M | -288K | -44.11M | |
| Invested capital | 0.24 | 0.68 | 0.13 | 13.42 | -2.84 | |
| Average receivables | 7.48M | 6.84M | 0 | 0 | 7.69M | |
| Average payables | 3.54M | 2.25M | 818.5K | 2.76M | 2.95M | |
| Average inventory | 275K | 0 | 0 | 0 | 366.5K | |
| Days sales outstanding | 189.91 | 0 | 0 | 0 | 104.1 | |
| Days payables outstanding | 1.87K | 0 | 142.26 | 8.82K | 208.57 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 76.14 | |
| Receivables turnover | 1.92 | 0 | 0 | 0 | 3.51 | |
| Payables turnover | 0.2 | 0 | 2.57 | 0.04 | 1.75 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 4.79 | |
| ROE | -0.5 | -2.36 | -1.32 | -26.45 | 5.18 | |
| Capex per share | 0 | 0 | 0 | 0 | -0.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.11 | 0.15 | 0.16 | 0.18 | |
| Net income per share | -0.37 | -0.21 | -0.13 | -0.13 | -0.17 | |
| Operating cash flow per share | -0.3 | -0.19 | -0.13 | -0.12 | -0.24 | |
| Free cash flow per share | -0.3 | -0.19 | -0.13 | -0.12 | -0.24 | |
| Cash per share | 0.97 | 0.88 | 0.67 | 0.62 | 0.45 | |
| Book value per share | -0.28 | -0.05 | -0.14 | -0.14 | -0.19 | |
| Tangible book value per share | -0.53 | -0.27 | -0.33 | -0.32 | -0.37 | |
| Share holders equity per share | -0.28 | -0.05 | -0.14 | -0.14 | -0.19 | |
| Interest debt per share | 0.51 | 0.49 | 0.44 | 0.42 | 0.41 | |
| Market cap | 466.22M | 647.92M | 707.69M | 771.84M | 552.58M | |
| Enterprise value | 417.67M | 631.13M | 724.89M | 791.38M | 577.26M | |
| P/E ratio | -3.13 | -7.15 | -11.32 | -11.4 | -6.34 | |
| Price to sales ratio | 203.15 | 52.55 | 38.8 | 36.61 | 22.91 | |
| POCF ratio | -15.55 | -32.01 | -45.77 | -49.76 | -17.77 | |
| PFCF ratio | -15.55 | -32.01 | -45.77 | -49.76 | -17.77 | |
| P/B Ratio | -16.7 | -122.85 | -42.03 | -43.91 | -21.8 | |
| PTB ratio | -16.7 | -122.85 | -42.03 | -43.91 | -21.8 | |
| EV to sales | 181.99 | 51.19 | 39.74 | 37.54 | 23.94 | |
| Enterprise value over EBITDA | -12.01 | -34.87 | -64.43 | -57.74 | -73.57 | |
| EV to operating cash flow | -13.93 | -31.18 | -46.88 | -51.02 | -18.56 | |
| EV to free cash flow | -13.93 | -31.18 | -46.88 | -51.02 | -18.56 | |
| Earnings yield | -0.08 | -0.03 | -0.02 | -0.02 | -0.04 | |
| Free cash flow yield | -0.06 | -0.03 | -0.02 | -0.02 | -0.06 | |
| Debt to equity | -1.73 | -9.35 | -2.92 | -2.84 | -1.93 | |
| Debt to assets | 0.37 | 0.37 | 0.4 | 0.4 | 0.44 | |
| Net debt to EBITDA | 1.4 | 0.93 | -1.53 | -1.43 | -3.15 | |
| Current ratio | 1.04 | 3.6 | 3.26 | 1.23 | 1.27 | |
| Interest coverage | -16.89 | -4.75 | -3.06 | -3.62 | -1.83 | |
| Income quality | 0.81 | 0.89 | 0.98 | 0.89 | 2.32 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 3.51 | 0.71 | 0.45 | 0.57 | 0.42 | |
| Intangibles to total assets | 0.19 | 0.18 | 0.19 | 0.18 | 0.2 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.73 | 0.21 | 0.15 | 0.14 | 0.1 | |
| Graham number | 1.53 | 0.48 | 0.63 | 0.64 | 0.85 | |
| ROIC | -1.65 | -0.41 | -0.36 | -0.38 | -0.62 | |
| Return on tangible assets | -0.35 | -0.21 | -0.16 | -0.16 | -0.24 | |
| Graham Net | -0.61 | -0.35 | -0.41 | -0.4 | -0.46 | |
| Working capital | 4.35M | 77.58M | 67.17M | 18.26M | 18.23M | |
| Tangible asset value | -52.73M | -29.56M | -40.59M | -40.8M | -48.05M | |
| Net current asset value | -56.07M | -32.44M | -43.37M | -44.11M | -51.17M | |
| Invested capital | -1.73 | -9.35 | -2.92 | -2.84 | -1.93 | |
| Average receivables | 1.21M | 5.29M | 9.38M | 12.99M | 19.17M | |
| Average payables | 3.16M | 2.76M | 2.77M | 2.23M | 2.02M | |
| Average inventory | 51K | 402K | 924.5K | 940K | 755K | |
| Days sales outstanding | 95.14 | 59.56 | 52.26 | 65.68 | 85.67 | |
| Days payables outstanding | 785.07 | 303.96 | 190.86 | 154.86 | 148.9 | |
| Days of inventory on hand | 33.02 | 68.9 | 89.61 | 56.53 | 57.13 | |
| Receivables turnover | 0.95 | 1.51 | 1.72 | 1.37 | 1.05 | |
| Payables turnover | 0.11 | 0.3 | 0.47 | 0.58 | 0.6 | |
| Inventory turnover | 2.73 | 1.31 | 1 | 1.59 | 1.58 | |
| ROE | 1.33 | 4.3 | 0.93 | 0.96 | 0.86 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CTIC Frequently Asked Questions
What is CTI BioPharma Corp. stock symbol ?
CTI BioPharma Corp. is a US stock , located in Seattle of Wa and trading under the symbol CTIC
What is CTI BioPharma Corp. stock quote today ?
CTI BioPharma Corp. stock price is $- today.
Is CTI BioPharma Corp. stock public?
Yes, CTI BioPharma Corp. is a publicly traded company.
Company Profile
- Volume Average 5.66M
- Market Capitalization 1.2B
- Employee 127
- CEO Dr. Adam R. Craig M.B.A., M.D., Ph.D.
- Headquarters Seattle,WA,US
- IPO Date 1997-03-21
-
Website
https://www.ctibiopharma.com 
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
